Table 6.
Randomized phase III trial of everolimus with best supportive care or placebo with best supportive care in metastatic renal cell cancer patients who have failed at least one vascular endothelial growth factor tyrosine kinase inhibitor [Motzer et al. 2008b].
Treatment | PFS | p value | OS | p value |
---|---|---|---|---|
Everolimus | 4.0 | 0.0001 | NR | NA |
Placebo | 1.9 | 8.8 |
NR, not reached; OS, overall survival; PFS, progression-free survival.